{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:00:20Z","timestamp":1792756820621,"version":"4.5.0"},"reference-count":113,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"am","delay-in-days":324,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100017540","name":"National Heart Lung and Blood Institute Division of Intramural Research","doi-asserted-by":"publisher","award":["HL141345"],"award-info":[{"award-number":["HL141345"]}],"id":[{"id":"10.13039\/100017540","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007271","name":"Health Science Center, University of Tennessee","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007271","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association Inc","doi-asserted-by":"publisher","award":["25TPA1475438"],"award-info":[{"award-number":["25TPA1475438"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ejphar.2025.178179","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T15:36:04Z","timestamp":1758123364000},"page":"178179","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Cardiac hypertrophy at the crossroads: Mechanistic insights and emerging multimodal therapeutic strategies"],"prefix":"10.1016","volume":"1006","author":[{"given":"Dharshini","family":"Kannan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheeja","family":"Rajasingh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parani","family":"Madasamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6172-4083","authenticated-orcid":false,"given":"Johnson","family":"Rajasingh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2025.178179_bib1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1080\/01913123.2022.2163016","article-title":"Calanus oil attenuates isoproterenol-induced cardiac hypertrophy by regulating myocardial remodeling and oxidative stress","volume":"47","author":"Abdellatif","year":"2023","journal-title":"Ultrastruct. Pathol."},{"key":"10.1016\/j.ejphar.2025.178179_bib2","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jacc.2015.05.058","article-title":"From contractile enhancement to pathological hypertrophy: Angiotensin II\u2013induced Nox2-mediated reactive oxygen species","author":"Ago","year":"2015","journal-title":"Am. Coll. Cardiol.Found."},{"key":"10.1016\/j.ejphar.2025.178179_bib3","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1161\/CIRCRESAHA.118.311217","article-title":"Clinical studies of cell therapy in cardiovascular medicine: recent developments and future directions","volume":"123","author":"Banerjee","year":"2018","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejphar.2025.178179_bib4","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.jshs.2020.11.009","article-title":"IGF1\u2013PI3K-induced physiological cardiac hypertrophy: Implications for new heart failure therapies, biomarkers, and predicting cardiotoxicity","volume":"10","author":"Bass-Stringer","year":"2021","journal-title":"J. sport health sci."},{"key":"10.1016\/j.ejphar.2025.178179_bib5","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/j.1365-2362.2007.01877.x","article-title":"HMG CoA reductase inhibition and left ventricular mass in hypertrophic cardiomyopathy: a randomized placebo-controlled pilot study","volume":"37","author":"Bauersachs","year":"2007","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.ejphar.2025.178179_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/cells12131780","article-title":"The microenvironment of the pathogenesis of cardiac hypertrophy","volume":"12","author":"Bazgir","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.ejphar.2025.178179_bib7","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.7150\/thno.21274","article-title":"Extracellular vesicles in cardiovascular theranostics","volume":"7","author":"Bei","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.ejphar.2025.178179_bib8","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.3390\/cells11213336","article-title":"Angiotensin II-induced signal transduction mechanisms for cardiac hypertrophy","volume":"11","author":"Bhullar","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.ejphar.2025.178179_bib9","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.tips.2008.01.003","article-title":"The Wnt\/frizzled\/GSK-3\u03b2 pathway: a novel therapeutic target for cardiac hypertrophy","volume":"29","author":"Blankesteijn","year":"2008","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejphar.2025.178179_bib10","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/HCO.0000000000000850","article-title":"RNA therapeutics for cardiovascular disease","volume":"36","author":"Boada","year":"2021","journal-title":"Curr. Opin. Cardiol."},{"key":"10.1016\/j.ejphar.2025.178179_bib11","doi-asserted-by":"crossref","DOI":"10.1161\/circ.150.suppl_1.4138992","article-title":"Beta blockers and calcium channel blockers in pre-symptomatic patients with hypertrophic cardiomyopathy: prevalence, discontinuation, and effectiveness","volume":"150","author":"Bradlow","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2025.178179_bib12","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1074\/jbc.RA118.006123","article-title":"Yes-associated protein (YAP) mediates adaptive cardiac hypertrophy in response to pressure overload","volume":"294","author":"Byun","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2025.178179_bib13","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1161\/HYPERTENSIONAHA.119.12998","article-title":"Long noncoding RNA\u2013DACH1 (dachshund homolog 1) regulates cardiac function by inhibiting SERCA2a (sarcoplasmic reticulum calcium ATPase 2a)","volume":"74","author":"Cai","year":"2019","journal-title":"Hypertension"},{"key":"10.1016\/j.ejphar.2025.178179_bib14","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1161\/CIRCULATIONAHA.124.070137","article-title":"RNA editing holds promise for hypertrophic cardiomyopathy therapy","volume":"150","author":"Carrier","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2025.178179_bib15","doi-asserted-by":"crossref","first-page":"165","DOI":"10.31083\/j.rcm2305165","article-title":"Cardiac hypertrophy: from pathophysiological mechanisms to heart failure development","volume":"23","author":"Caturano","year":"2022","journal-title":"Rev. Cardiovasc. Med."},{"key":"10.1016\/j.ejphar.2025.178179_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2023.149367","article-title":"Astragaloside IV alleviates LPS-induced cardiomyocyte hypertrophy and collagen expression associated with CCL2-mediated activation of NF-\u03baB signaling pathway","volume":"693","author":"Chai","year":"2024","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejphar.2025.178179_bib17","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/MAJ.0b013e31822993ff","article-title":"Angiotensin II type-1 receptor-JAK\/STAT pathway mediates the induction of visfatin in angiotensin II-induced cardiomyocyte hypertrophy","volume":"343","author":"Chang","year":"2012","journal-title":"Am. J. Med. Sci."},{"key":"10.1016\/j.ejphar.2025.178179_bib18","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.bbadis.2019.01.020","article-title":"Nrf2 deficiency aggravates Angiotensin II-induced cardiac injury by increasing hypertrophy and enhancing IL-6\/STAT3-dependent inflammation","volume":"1865","author":"Chen","year":"2019","journal-title":"Biochim. Biophys. Acta, Mol. Basis Dis."},{"key":"10.1016\/j.ejphar.2025.178179_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.111022","article-title":"Qingda granule attenuates angiotensin II-induced cardiac hypertrophy and apoptosis and modulates the PI3K\/AKT pathway","volume":"133","author":"Cheng","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejphar.2025.178179_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24091647","article-title":"Nelumbo nucifera receptaculum extract suppresses angiotensin II-induced cardiomyocyte hypertrophy","volume":"24","author":"Cho","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.ejphar.2025.178179_bib21","article-title":"Global burden of cardiovascular diseases: projections from 2025 to 2050","author":"Chong","year":"2024","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.ejphar.2025.178179_bib22","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ijcard.2018.07.016","article-title":"Overexpression of miR-135b attenuates pathological cardiac hypertrophy by targeting CACNA1C","volume":"269","author":"Chu","year":"2018","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ejphar.2025.178179_bib23","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2147\/VHRM.S1899","article-title":"Angiotensin II receptor blockers and cardiovascular protection: focus on left ventricular hypertrophy regression and atrial fibrillation prevention","volume":"4","author":"Cuspidi","year":"2008","journal-title":"Vasc. Health Risk Manag."},{"key":"10.1016\/j.ejphar.2025.178179_bib24","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1161\/01.HYP.32.6.989","article-title":"Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention for Endpoint Reduction in Hypertension","volume":"32","author":"Dahl\u00f6f","year":"1998","journal-title":"Hypertension"},{"key":"10.1016\/j.ejphar.2025.178179_bib25","first-page":"119","article-title":"The role of miR-1 in the heart: from cardiac morphogenesis to physiological function","volume":"4","author":"Deng","year":"2014","journal-title":"Hum. Genet. Embryol."},{"key":"10.1016\/j.ejphar.2025.178179_bib26","doi-asserted-by":"crossref","first-page":"856","DOI":"10.3390\/cells13100856","article-title":"Role of vasoactive hormone-induced signal transduction in cardiac hypertrophy and heart failure","volume":"13","author":"Dhalla","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.ejphar.2025.178179_bib27","doi-asserted-by":"crossref","first-page":"22","DOI":"10.2174\/1573402114666180918102735","article-title":"Three generations of \u03b2-blockers: history, class differences and clinical applicability","volume":"15","author":"do Vale","year":"2019","journal-title":"Curr. Hypertens. Rev."},{"key":"10.1016\/j.ejphar.2025.178179_bib28","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1161\/HYPERTENSIONAHA.109.139519","article-title":"Reciprocal repression between microRNA-133 and calcineurin regulates cardiac hypertrophy: a novel mechanism for progressive cardiac hypertrophy","volume":"55","author":"Dong","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.ejphar.2025.178179_bib29","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1161\/CIRCRESAHA.107.162800","article-title":"Molecular mechanisms of angiotensin II\u2013mediated mitochondrial dysfunction: linking mitochondrial oxidative damage and vascular endothelial dysfunction","volume":"102","author":"Doughan","year":"2008","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejphar.2025.178179_bib30","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.yexcr.2012.11.015","article-title":"miR-150 regulates high glucose-induced cardiomyocyte hypertrophy by targeting the transcriptional co-activator p300","volume":"319","author":"Duan","year":"2013","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.ejphar.2025.178179_bib31","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1016\/j.jacc.2021.07.065","article-title":"Randomized trial of metoprolol in patients with obstructive hypertrophic cardiomyopathy","volume":"78","author":"Dybro","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2025.178179_bib32","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1080\/01913123.2023.2175944","article-title":"Flaxseed lignans alleviates isoproterenol-induced cardiac hypertrophy by regulating myocardial remodeling and oxidative stress","volume":"47","author":"Elsayed","year":"2023","journal-title":"Ultrastruct. Pathol."},{"key":"10.1016\/j.ejphar.2025.178179_bib33","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41392-022-00950-y","article-title":"Advances in COVID-19 mRNA vaccine development","volume":"7","author":"Fang","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejphar.2025.178179_bib34","doi-asserted-by":"crossref","DOI":"10.4061\/2011\/290561","article-title":"Current trends in implantable left ventricular assist devices","volume":"2011","author":"Garbade","year":"2011","journal-title":"Cardiol. Res. Pract."},{"key":"10.1016\/j.ejphar.2025.178179_bib35","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1038\/s41467-019-11777-7","article-title":"Circular RNA CircFndc3b modulates cardiac repair after myocardial infarction via FUS\/VEGF-A axis","volume":"10","author":"Garikipati","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejphar.2025.178179_bib36","doi-asserted-by":"crossref","first-page":"186","DOI":"10.5966\/sctm.2015-0101","article-title":"Concise review: review and perspective of cell dosage and routes of administration from preclinical and clinical studies of stem cell therapy for heart disease","volume":"5","author":"Golpanian","year":"2016","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.ejphar.2025.178179_bib37","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/S0140-6736(16)00082-9","article-title":"Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial","volume":"387","author":"Greenberg","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2025.178179_bib38","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jchf.2013.09.008","article-title":"Design of a phase 2b trial of intracoronary administration of AAV1\/SERCA2a in patients with advanced heart failure: the CUPID 2 trial (calcium up-regulation by percutaneous administration of gene therapy in cardiac disease phase 2b)","volume":"2","author":"Greenberg","year":"2014","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.ejphar.2025.178179_bib39","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1111\/jcmm.13076","article-title":"CD38 promotes angiotensin II\u2010induced cardiac hypertrophy","volume":"21","author":"Guan","year":"2017","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.ejphar.2025.178179_bib40","first-page":"79","article-title":"Ginseng inhibits cardiomyocyte hypertrophy and heart failure via NHE-1 inhibition and attenuation of calcineurin activation","volume":"4","author":"Guo","year":"2011","journal-title":"Circulation: Heart Fail."},{"key":"10.1016\/j.ejphar.2025.178179_bib41","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1161\/CIRCRESAHA.109.211458","article-title":"Development of a drug screening platform based on engineered heart tissue","volume":"107","author":"Hansen","year":"2010","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejphar.2025.178179_bib42","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/1843142","article-title":"A review of ginseng clinical trials registered in the WHO international clinical trials registry platform","volume":"2018","author":"He","year":"2018","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.ejphar.2025.178179_bib43","doi-asserted-by":"crossref","first-page":"129","DOI":"10.4103\/1995-705X.201784","article-title":"Statin induced regression of cardiomyopathy trial: a randomized, placebo-controlled double-blind trial","volume":"17","author":"Hersi","year":"2016","journal-title":"Heart Views"},{"key":"10.1016\/j.ejphar.2025.178179_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2023.116844","article-title":"Dohongsamul-tang inhibits cardiac remodeling and fibrosis through calcineurin\/NFAT and TGF-\u03b2\/Smad2 signaling in cardiac hypertrophy","volume":"318","author":"Hong","year":"2024","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.ejphar.2025.178179_bib45","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.pharmthera.2012.06.006","article-title":"Regression of pathological cardiac hypertrophy: signaling pathways and therapeutic targets","volume":"135","author":"Hou","year":"2012","journal-title":"Pharmacol. Therapeut."},{"key":"10.1016\/j.ejphar.2025.178179_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1444940","article-title":"Extracellular vesicular microRNAs and cardiac hypertrophy","volume":"15","author":"Hu","year":"2025","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.ejphar.2025.178179_bib47","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1161\/CIRCULATIONAHA.118.038361","article-title":"Loss of super-enhancer-regulated circRNA Nfix induces cardiac regeneration after myocardial infarction in adult mice","volume":"139","author":"Huang","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2025.178179_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.723236","article-title":"Stem cell-derived exosomes potential therapeutic roles in cardiovascular diseases","volume":"8","author":"Jayaraman","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.ejphar.2025.178179_bib49","article-title":"Long non-coding RNA-ROR mediates the reprogramming in cardiac hypertrophy","volume":"11","author":"Jiang","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2025.178179_bib50","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3390\/metabo12010070","article-title":"Gene therapy targeting PCSK9","volume":"12","author":"Katzmann","year":"2022","journal-title":"Metabolites"},{"key":"10.1016\/j.ejphar.2025.178179_bib51","doi-asserted-by":"crossref","first-page":"3767","DOI":"10.1113\/JP271161","article-title":"Pathological vs. physiological cardiac hypertrophy","volume":"593","author":"Kavazis","year":"2015","journal-title":"J. Physiol."},{"key":"10.1016\/j.ejphar.2025.178179_bib52","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1159\/000526792","article-title":"A discrepancy: calcium channel blockers are effective for the treatment of hypertensive left ventricular hypertrophy but not as effective for prevention of heart failure","volume":"31","author":"Koracevic","year":"2022","journal-title":"Med. Princ. Pract."},{"key":"10.1016\/j.ejphar.2025.178179_bib53","doi-asserted-by":"crossref","DOI":"10.1172\/JCI159179","article-title":"MicroRNAs as therapeutic targets in cardiovascular disease","volume":"132","author":"Laggerbauer","year":"2022","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejphar.2025.178179_bib54","doi-asserted-by":"crossref","first-page":"953","DOI":"10.3389\/fphys.2018.00953","article-title":"RNA therapeutics in cardiovascular precision medicine","volume":"9","author":"Laina","year":"2018","journal-title":"Front. Physiol."},{"key":"10.1016\/j.ejphar.2025.178179_bib55","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1177\/108155890405200433","article-title":"Statin therapy for cardiac hypertrophy and heart failure","volume":"52","author":"Liao","year":"2004","journal-title":"J Investig Med"},{"key":"10.1016\/j.ejphar.2025.178179_bib56","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.biopha.2018.09.146","article-title":"Overexpression of miR-142-3p improves mitochondrial function in cardiac hypertrophy","volume":"108","author":"Liu","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejphar.2025.178179_bib57","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s00726-018-2583-x","article-title":"Alamandine attenuates hypertension and cardiac hypertrophy in hypertensive rats","volume":"50","author":"Liu","year":"2018","journal-title":"Amino Acids"},{"key":"10.1016\/j.ejphar.2025.178179_bib58","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.gene.2018.01.047","article-title":"A new miRNA regulator, miR-672, reduces cardiac hypertrophy by inhibiting JUN expression","volume":"648","author":"Lu","year":"2018","journal-title":"Gene"},{"key":"10.1016\/j.ejphar.2025.178179_bib59","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.omtn.2017.12.018","article-title":"The lncRNA Plscr4 controls cardiac hypertrophy by regulating miR-214","volume":"10","author":"Lv","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ejphar.2025.178179_bib60","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/s41434-020-0171-7","article-title":"Investigation of the safety and feasibility of AAV1\/SERCA2a gene transfer in patients with chronic heart failure supported with a left ventricular assist device\u2013the SERCA-LVAD TRIAL","volume":"27","author":"Lyon","year":"2020","journal-title":"Gene Ther."},{"key":"10.1016\/j.ejphar.2025.178179_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115275","article-title":"Resveratrol prevents Ang II-induced cardiac hypertrophy by inhibition of NF-\u03baB signaling","volume":"165","author":"Ma","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejphar.2025.178179_bib62","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202004661","article-title":"Therapeutic delivery of Pip4k2c\u2010modified mRNA attenuates cardiac hypertrophy and fibrosis in the failing heart","volume":"8","author":"Magadum","year":"2021","journal-title":"Adv. Sci."},{"key":"10.1016\/j.ejphar.2025.178179_bib63","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1177\/15353702231151960","article-title":"Therapeutic potentials of stem cell\u2013derived exosomes in cardiovascular diseases","volume":"248","author":"Mani","year":"2023","journal-title":"Exp. Biol. Med."},{"key":"10.1016\/j.ejphar.2025.178179_bib64","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1186\/s12951-022-01630-3","article-title":"Heart-targeting exosomes from human cardiosphere-derived cells improve the therapeutic effect on cardiac hypertrophy","volume":"20","author":"Mao","year":"2022","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.ejphar.2025.178179_bib65","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1161\/CIRCRESAHA.117.311059","article-title":"Hypertrophic cardiomyopathy: Genetics, pathogenesis, clinical manifestations, diagnosis, and therapy","volume":"121","author":"Marian","year":"2017","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejphar.2025.178179_bib66","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3389\/fphar.2017.00220","article-title":"Cardioprotective action of Ginkgo biloba extract against sustained \u03b2-adrenergic stimulation occurs via activation of M(2)\/NO pathway","volume":"8","author":"Mesquita","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178179_bib67","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20171430","article-title":"miR-139-5p inhibits isoproterenol-induced cardiac hypertrophy by targetting c-Jun","volume":"38","author":"Ming","year":"2018","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.ejphar.2025.178179_bib68","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1146\/annurev.physiol.63.1.391","article-title":"Cytoplasmic signaling pathways that regulate cardiac hypertrophy","volume":"63","author":"Molkentin","year":"2001","journal-title":"Annu. Rev. Physiol."},{"key":"10.1016\/j.ejphar.2025.178179_bib69","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.yjmcc.2013.07.010","article-title":"Impact of the renin\u2013angiotensin system on cardiac energy metabolism in heart failure","volume":"63","author":"Mori","year":"2013","journal-title":"J. Mol. Cellular Cardiol."},{"key":"10.1016\/j.ejphar.2025.178179_bib70","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3390\/life13010043","article-title":"Parkia speciosa Hassk. empty pod extract prevents cardiomyocyte hypertrophy by inhibiting MAPK and calcineurin-NFATC3 signaling pathways","volume":"13","author":"Mustafa","year":"2022","journal-title":"Life"},{"key":"10.1016\/j.ejphar.2025.178179_bib71","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1111\/j.1365-2362.2010.02349.x","article-title":"Atorvastatin and cardiac hypertrophy and function in hypertrophic cardiomyopathy: a pilot study","volume":"40","author":"Nagueh","year":"2010","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.ejphar.2025.178179_bib72","doi-asserted-by":"crossref","first-page":"4765","DOI":"10.3390\/ijms24054765","article-title":"Cardiac roles of serotonin (5-HT) and 5-HT-receptors in health and disease","volume":"24","author":"Neumann","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2025.178179_bib73","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1139\/cjpp-2019-0566","article-title":"Mechanisms for the transition from physiological to pathological cardiac hypertrophy","volume":"98","author":"Oldfield","year":"2020","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178179_bib74","doi-asserted-by":"crossref","first-page":"5305","DOI":"10.1038\/sj.emboj.7601417","article-title":"TRPC3 and TRPC6 are essential for angiotensin II\u2010induced cardiac hypertrophy","volume":"25","author":"Onohara","year":"2006","journal-title":"The EMBO J."},{"key":"10.1016\/j.ejphar.2025.178179_bib75","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41569-019-0244-8","article-title":"Counter-regulatory renin\u2013angiotensin system in cardiovascular disease","volume":"17","author":"Paz Ocaranza","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.ejphar.2025.178179_bib76","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2353\/jmoldx.2009.080082","article-title":"The effects of candesartan on left ventricular hypertrophy and function in nonobstructive hypertrophic cardiomyopathy: a pilot, randomized study","volume":"11","author":"Penicka","year":"2009","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.ejphar.2025.178179_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2024.113961","article-title":"scaRNA20 promotes pseudouridylatory modification of small nuclear snRNA U12 and improves cardiomyogenesis","volume":"436","author":"Perales","year":"2024","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.ejphar.2025.178179_bib78","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.amjcard.2024.10.029","article-title":"Comparative influences of beta blockers and verapamil on cardiac outcomes in hypertrophic cardiomyopathy","volume":"235","author":"Pinto","year":"2025","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ejphar.2025.178179_bib79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/ijmm.2025.5500","article-title":"Thymoquinone mitigates cardiac hypertrophy by activating adaptive autophagy via the PPAR-\u03b3\/14-3-3\u03b3 pathway","volume":"55","author":"Qiu","year":"2025","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.ejphar.2025.178179_bib80","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1073\/pnas.92.9.3864","article-title":"Structural interpretation of the mutations in the beta-cardiac myosin that have been implicated in familial hypertrophic cardiomyopathy","volume":"92","author":"Rayment","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.ejphar.2025.178179_bib81","doi-asserted-by":"crossref","first-page":"32","DOI":"10.14797\/mdcj-9-1-32","article-title":"Ventricular assist devices (VAD) therapy: new technology, new hope?","volume":"9","author":"Rodriguez","year":"2013","journal-title":"Methodist DeBakey cardiovasc. J."},{"key":"10.1016\/j.ejphar.2025.178179_bib82","unstructured":"Ruilope, L., Cerezo, C., Segura, J. & Garcia-Donaire, J. Calcium Channel Blockers and Cardiovascular Protection."},{"key":"10.1016\/j.ejphar.2025.178179_bib83","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.tcm.2016.02.004","article-title":"MicroRNA: a new therapeutic strategy for cardiovascular diseases","volume":"26","author":"Samanta","year":"2016","journal-title":"Trends Cardiovasc. Med."},{"key":"10.1016\/j.ejphar.2025.178179_bib84","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3389\/fphar.2020.00422","article-title":"Herbal medicine for cardiovascular diseases: efficacy, mechanisms, and safety","volume":"11","author":"Shaito","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178179_bib85","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.yjmcc.2011.02.012","article-title":"Angiotensin-II type 1 receptor and NOX2 mediate TCF\/LEF and CREB dependent WISP1 induction and cardiomyocyte hypertrophy","volume":"50","author":"Shanmugam","year":"2011","journal-title":"J. Mol. Cellular Cardiol."},{"key":"10.1016\/j.ejphar.2025.178179_bib86","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3390\/biom8030054","article-title":"A novel class of tRNA-derived small non-coding RNAs respond to myocardial hypertrophy and contribute to intergenerational inheritance","volume":"8","author":"Shen","year":"2018","journal-title":"Biomolecules"},{"key":"10.1016\/j.ejphar.2025.178179_bib87","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1002\/cbin.11685","article-title":"MiR\u201026a\u20105p alleviates cardiac hypertrophy and dysfunction via targeting ADAM17","volume":"45","author":"Shi","year":"2021","journal-title":"Cell Biol. Int."},{"key":"10.1016\/j.ejphar.2025.178179_bib88","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.yjmcc.2016.06.001","article-title":"Physiological and pathological cardiac hypertrophy","volume":"97","author":"Shimizu","year":"2016","journal-title":"J. Mol. Cellular Cardiol."},{"key":"10.1016\/j.ejphar.2025.178179_bib89","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.omtn.2020.06.024","article-title":"circRNA Hipk3 induces cardiac regeneration after myocardial infarction in mice by binding to Notch1 and miR-133a","volume":"21","author":"Si","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ejphar.2025.178179_bib90","article-title":"Emerging therapeutic strategies in cardiovascular diseases","volume":"16","author":"Singh","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.ejphar.2025.178179_bib91","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/0092-8674(94)90054-X","article-title":"Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere","volume":"77","author":"Thierfelder","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2025.178179_bib92","doi-asserted-by":"crossref","first-page":"188","DOI":"10.15420\/aer.2016:30:2","article-title":"ICD therapy for primary prevention in hypertrophic cardiomyopathy","volume":"5","author":"Trivedi","year":"2016","journal-title":"Arrhythmia Electrophysiol. Rev."},{"key":"10.1016\/j.ejphar.2025.178179_bib93","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1080\/13813455.2023.2252200","article-title":"Dapagliflozin attenuates high glucose-and hypoxia\/reoxygenation-induced injury via activating AMPK\/mTOR-OPA1-mediated mitochondrial autophagy in H9c2 cardiomyocytes","volume":"130","author":"Tu","year":"2024","journal-title":"Arch. Physiol. Biochem."},{"key":"10.1016\/j.ejphar.2025.178179_bib94","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s12877-017-0575-4","article-title":"Effectiveness and safety of beta blockers in the management of hypertension in older adults: a systematic review to help reduce inappropriate prescribing","volume":"17","author":"V\u00f6gele","year":"2017","journal-title":"BMC Geriatr."},{"key":"10.1016\/j.ejphar.2025.178179_bib95","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1536\/ihj.16-020","article-title":"microRNA-10a targets T-box 5 to inhibit the development of cardiac hypertrophy","volume":"58","author":"Wang","year":"2017","journal-title":"Int. Heart J."},{"key":"10.1016\/j.ejphar.2025.178179_bib96","first-page":"994","article-title":"Construction and analysis of the lncRNA-miRNA-mRNA network based on competitive endogenous RNA reveals functional genes in heart failure","volume":"19","author":"Wang","year":"2019","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.ejphar.2025.178179_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.107898","article-title":"From molecular chaos to precision medicine in the treatment of cardiac hypertrophy: a rational use of natural products by integrating artificial intelligence and multi-omics data","volume":"219","author":"Wang","year":"2025","journal-title":"Pharmacol. Res. : Off J. Ital. Pharmacol. Soc."},{"key":"10.1016\/j.ejphar.2025.178179_bib98","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/cdd.2017.61","article-title":"Circular RNA mediates cardiomyocyte death via miRNA-dependent upregulation of MTP18 expression","volume":"24","author":"Wang","year":"2017","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.ejphar.2025.178179_bib99","doi-asserted-by":"crossref","DOI":"10.1002\/adtp.202300451","article-title":"LTBP2 knockdown ameliorates cardiac fibrosis and apoptosis via attenuating NF\u2010\u03baB signaling pathway and oxidative stress in mice with cardiac hypertrophy","volume":"7","author":"Wang","year":"2024","journal-title":"Adv. Therapeut."},{"key":"10.1016\/j.ejphar.2025.178179_bib100","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/nm.4179","article-title":"The long noncoding RNA Chaer defines an epigenetic checkpoint in cardiac hypertrophy","volume":"22","author":"Wang","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2025.178179_bib101","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.cardiores.2006.02.004","article-title":"Contribution of PI 3-kinase isoforms to angiotensin II-and \u03b1-adrenoceptor-mediated signalling pathways in cardiomyocytes","volume":"71","author":"Wenzel","year":"2006","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ejphar.2025.178179_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116241","article-title":"The water extract of Amydrium sinense (Engl.) H. Li ameliorates Isoproterenol-induced cardiac hypertrophy through inhibiting the NF-\u03baB signaling pathway","volume":"172","author":"Wu","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejphar.2025.178179_bib103","article-title":"Loganin inhibits angiotensin II-induced cardiac hypertrophy through the JAK2\/STAT3 and NF-\u03baB signaling pathways","volume":"12","author":"Xu","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178179_bib104","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.yjmcc.2019.12.013","article-title":"LncRNA-Mhrt regulates cardiac hypertrophy by modulating the miR-145a-5p\/KLF4\/myocardin axis","volume":"139","author":"Xu","year":"2020","journal-title":"J. Mol. Cellular Cardiol."},{"key":"10.1016\/j.ejphar.2025.178179_bib105","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/cbin.11298","article-title":"LncRNA SNHG1 exerts a protective role in cardiomyocytes hypertrophy via targeting miR\u201015a\u20105p\/HMGA1 axis","volume":"44","author":"Yan","year":"2020","journal-title":"Cell Biol. Int."},{"key":"10.1016\/j.ejphar.2025.178179_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114799","article-title":"The role of endothelial cell in cardiac hypertrophy: focusing on angiogenesis and intercellular crosstalk","volume":"163","author":"Yang","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejphar.2025.178179_bib107","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1016\/j.jacc.2003.12.051","article-title":"Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy","volume":"43","author":"Yasunari","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2025.178179_bib108","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1161\/CIRCRESAHA.119.315861","article-title":"Celastrol attenuates angiotensin II\u2013induced cardiac remodeling by targeting STAT3","volume":"126","author":"Ye","year":"2020","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejphar.2025.178179_bib109","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1161\/01.RES.0000240147.49390.61","article-title":"An angiotensin II type 1 receptor mutant lacking epidermal growth factor receptor transactivation does not induce angiotensin II\u2013mediated cardiac hypertrophy","volume":"99","author":"Zhai","year":"2006","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejphar.2025.178179_bib110","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1172\/JCI25330","article-title":"Cardiac-specific overexpression of AT1 receptor mutant lacking G\u03b1q\/G\u03b1i coupling causes hypertrophy and bradycardia in transgenic mice","volume":"115","author":"Zhai","year":"2005","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejphar.2025.178179_bib111","first-page":"173","article-title":"Role of mitogen-activated protein kinase in cardiac hypertrophy and heart failure","volume":"8","author":"Zhang","year":"2003","journal-title":"Exp. Clin. Cardiol."},{"key":"10.1016\/j.ejphar.2025.178179_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107698","article-title":"Current state and future perspective of cardiovascular medicines derived from natural products","volume":"216","author":"Zhao","year":"2020","journal-title":"Pharmacol. Therapeut."},{"key":"10.1016\/j.ejphar.2025.178179_bib113","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.608523","article-title":"Role of PI3-kinase in angiotensin II-induced cardiac hypertrophy: class I versus class III","volume":"12","author":"Zhong","year":"2021","journal-title":"Front. Pharmacol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925009331?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925009331?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T04:36:15Z","timestamp":1780202175000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299925009331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":113,"alternative-id":["S0014299925009331"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.178179","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiac hypertrophy at the crossroads: Mechanistic insights and emerging multimodal therapeutic strategies","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.178179","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"178179"}}